| iogen to Be Presented at Natural Products Expo West |
|
|
|
|
Scientific Bio-Logics Welcomes iogen Tuesday March 9, 2010, 8:30 am EST
MEDFIELD, MA--(Marketwire - 03/09/10) - Symbollon Pharmaceuticals, Inc. (OTC.BB:SYMBA) (www.symbollon.com) is pleased to announce that Scientific Bio-Logics of Huntington Beach, California will be featuring iogen as a spotlight product in the prestigious Natural Products Expo West Trade Show being held in Anaheim, CA on March 12-14, 2010.
Symbollon has teamed up with Scientific Bio-Logics, a professional marketing and distribution firm that will have a significant presence at the Natural Products Expo West Trade Show. iogen will be featured in their booth as a spotlight product, and will be introduced to the wholesale market and industry professionals that will be attending the show. "Our Company is very committed to pursuing the most effective distribution channels available to us, and we are very excited to have a presence at the Natural Products Expo West Trade Show this weekend. To be associated with Scientific Bio-Logics provides our company with a gateway directly into the natural products industry with substantial credibility," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. Paul continued, "As we have just recently launched our own retail website for iogen, we will be looking for quality distributors, such as Scientific Bio-Logics, to expand our reach into the retail sector." About Natural Products Expo West About Scientific Bio-Logics About Symbollon Pharmaceuticals, Inc. (OTC.BB:SYMBA) Forward-Looking Statement This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize iogen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) we will be able to complete the acquisition of New Zealand Pure under the terms of the letter of intent, (v) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.
|













































